purpos
explor
clinic
microbiolog
immunolog
featur
patient
fever
thrombocytopenia
method
patient
unexplain
fever
thrombocytopenia
enrol
virus
detect
use
realtim
pcr
bacteria
measur
cultur
method
serum
cytokin
platelet
antibodi
igg
paigg
helicobact
pylori
hp
detect
use
elisa
result
pathogen
detect
patient
includ
singl
fungalviralbacteri
infect
multipl
infect
pathogen
could
unidentifi
case
cytokin
includ
interleukin
il
platelet
activ
factor
paf
paigg
significantli
higher
patient
compar
healthi
control
p
p
princip
compon
analys
extract
four
group
paramet
strong
posit
predict
valu
reveal
diseas
statu
evalu
would
accur
combin
platelet
paramet
inflammatori
biomark
eventfre
surviv
ef
indic
time
platelet
elev
therapi
highest
patient
singl
bacteri
fungal
infect
ef
affect
level
cytokin
paigg
conclus
differ
immun
function
may
main
factor
affect
prognosi
patient
fever
thrombocytopenia
treatment
base
precis
etiolog
diagnosi
import
therapeut
efficaci
fever
thrombocytopenia
frequent
symptom
patient
viral
infect
sever
fever
thrombocytopenia
syndrom
sft
caus
novel
bunyaviru
initi
identifi
sft
produc
broad
spectrum
clinic
manifest
rang
acut
selflimit
febril
ill
sever
diseas
report
fatal
rate
vari
due
poor
prognosi
higher
mortal
sft
quickli
becom
emerg
infecti
diseas
arous
extens
surveil
public
health
current
sft
togeth
mening
syndrom
respiratori
syndrom
primari
three
syndrom
monitor
clinic
unlik
inflammatori
diseas
etiolog
fever
thrombocytopenia
quit
complic
thrombocytopenia
may
aris
due
lack
platelet
product
retent
platelet
plt
spleen
platelet
destruct
increas
use
dilut
plt
clinic
thrombocytopenia
patient
diagnos
primari
immun
thrombocytopenia
itp
defin
peripher
blood
platelet
count
l
absenc
obviou
caus
thrombocytopenia
etiolog
itp
complic
physician
seldom
reli
etiolog
formul
treatment
plan
difficult
explain
patient
poor
therapeut
efficaci
fever
common
featur
consequ
itp
patient
viral
infect
evid
regard
crossreact
virusspecif
antibodi
normal
platelet
antigen
firstli
obtain
patient
develop
itp
contract
human
immun
defici
viru
varicellazost
viru
infect
sinc
discov
thrombocytopenia
viral
infect
occur
success
thrombocytopenia
major
clinic
sign
found
viral
infecti
diseas
includ
zika
viru
hepat
bhepat
c
viru
dengu
viru
epsteinbarr
viru
viru
novel
bunyaviru
previou
studi
show
patient
influenza
viru
ab
parainfluenza
viru
infect
tend
lower
plt
count
patient
respiratori
viral
infect
patient
human
metapneumoviru
parainfluenza
viru
coronaviru
adenoviru
infect
show
signific
chang
plt
count
patient
thrombocytopenia
caus
viral
infect
transient
without
seriou
bleed
spontan
resolv
within
week
without
treatment
howev
patient
sever
bleed
syndrom
wors
prognosi
mechan
remain
elucid
thrombocytopenia
also
common
complic
bacteri
infect
direct
interact
platelet
bacteria
may
contribut
thrombocytopenia
helicobact
pylori
hp
proven
import
bacterium
caus
itp
addit
observ
salmonella
surviv
replic
macrophag
spread
lymphat
vessel
spleen
bone
marrow
thrombocytopenia
may
associ
hemophagocyt
histiocyt
bone
marrow
fecal
microbi
transplant
may
also
lead
thrombocytopenia
inflamm
staphylococcu
aureu
activ
platelet
sever
surfaceexpress
protein
bind
adher
platelet
caus
platelet
activ
aggreg
result
thrombocytopenia
unfortun
role
bacteri
infect
thrombocytopenia
often
clinic
ignor
viralbacteri
antigen
may
recogn
similar
platelet
antigen
process
term
molecular
mimicri
give
rise
crossreact
antiplatelet
autoantibodi
platelet
bound
autoantibodi
subsequ
recogn
phagocyt
bear
receptor
result
enhanc
antibodymedi
platelet
phagocytosi
destruct
primarili
spleen
patient
itp
autoantibodi
target
platelet
surfac
glycoprotein
primarili
gpiibiiia
gpibix
lead
fcdepend
clearanc
via
macrophag
platelet
express
fccriia
igg
receptor
use
identifi
immun
complex
ic
fccriia
involv
initi
strong
effector
function
leukocyt
includ
cytokin
releas
antibodydepend
cellmedi
pathogen
kill
ic
intern
critic
immun
inflammatori
respons
viru
bacteria
activ
platelet
via
fccriia
play
import
role
interact
platelet
pathogen
infect
polymorph
directli
affect
suscept
sever
infect
howev
relationship
among
platelet
autoantibodi
cytokin
paramet
associ
infect
still
clear
mani
question
regard
pathophysiolog
mechan
diagnosi
natur
histori
manag
itp
remain
resolv
obscur
etiolog
mechan
thrombocytopenia
greatli
affect
therapeut
efficaci
firstlin
therapi
itp
consist
corticosteroid
without
intraven
immunoglobulin
patient
respond
other
nowaday
valuabl
biomark
predict
therapeut
efficaci
etiolog
diagnosi
thrombocytopenia
may
benefici
treatment
itp
caus
viral
infect
accur
etiolog
diagnosi
reduc
amount
antibiot
use
unfortun
diagnosi
itp
still
base
exclus
relationship
among
etiolog
fever
thrombocytopenia
intrins
immun
mechan
therapeut
efficaci
remain
elucid
clarifi
issu
patient
unexplain
fever
thrombocytopenia
enrol
studi
associ
among
etiolog
platelet
autoantibodi
cytokin
express
therapeut
efficaci
investig
aim
determin
valuabl
paramet
mirror
pathogenesi
predict
therapeut
efficaci
thrombocytopenia
period
januari
june
patient
unexplain
fever
bodi
temperatur
thrombocytopenia
platelet
count
l
enrol
studi
patient
solid
tumor
leukemia
liver
diseas
upper
lower
gastrointestin
traumat
bleed
exclud
ten
healthi
volunt
select
control
studi
approv
ethic
committe
first
affili
hospit
shantou
univers
medic
colleg
inform
consent
obtain
patient
sampl
collect
onset
diseas
treatment
nucleic
acid
serum
sampl
extract
use
viral
dnarna
magnet
bead
extract
kit
tianlong
china
nucleic
acid
extract
instrument
tianlong
china
singletub
realtim
revers
transcript
polymeras
chain
reaction
pcr
strategi
onestep
rtpcr
kit
appli
biosystem
usa
use
detect
virus
bunyaviru
detect
use
sever
fever
thrombocytopenia
syndrom
viru
sftsv
bunyaviru
real
time
rtpcr
kit
liferiv
china
human
parvoviru
detect
use
human
parvoviru
nucleic
acid
detect
kit
daangen
china
pcr
amplif
perform
use
realtim
pcr
system
appli
biosystem
usa
accord
manufactur
instruct
bacteria
identif
blood
sputum
specimen
patient
cultur
accord
nation
standard
protocol
china
specimen
inocul
blood
agar
eosin
methylen
blue
agar
chocol
agar
incub
h
coloni
identif
undertaken
use
vitek
compact
system
franc
helicobact
pylori
detect
use
commerci
kit
human
antihelicobact
pylori
antibodi
igg
elisa
kit
cusabio
china
paigg
six
cytokin
paf
interleukin
il
serum
sampl
detect
use
human
plateletassoci
igg
antibodi
paigg
elisa
kit
shanghai
jingkang
china
human
platelet
activ
factor
elisa
kit
dakew
china
human
precoat
elisa
kit
cusabio
china
accord
manufactur
instruct
absorb
valu
six
cytokin
measur
use
infinit
pro
micropl
reader
tecan
switzerland
convert
concentr
valu
accord
reagent
instruct
sensit
paigg
paf
detect
ngml
pgml
pgml
pgml
pgml
pgml
respect
statist
analys
perform
use
spss
softwar
continu
variabl
normal
distribut
use
mean
standard
deviat
sd
describ
compar
use
multipl
varianc
multipl
sampl
median
interquartil
rang
iqr
use
describ
nonnorm
distribut
comparison
base
mannwhitney
u
test
two
group
correl
serum
cytokin
paramet
obtain
use
nonparametr
rankbas
spearman
correl
coeffici
princip
compon
analysi
pca
perform
obtain
signific
princip
compon
accur
reflect
statu
thrombocytopenia
receiv
oper
characterist
roc
curv
analysi
use
determin
distinguish
use
biomark
ef
calcul
date
complet
recoveri
platelet
count
return
normal
rang
first
event
caus
recurr
death
last
followup
surviv
curv
calcul
use
kaplanmei
method
surviv
compar
use
mantel
logrank
test
thrombocytopenia
without
improv
analyz
use
binari
logist
regress
level
statist
signific
set
tabl
tabl
pathogen
could
measur
case
patient
patient
treat
antimicrobi
use
antibiot
quinolon
follow
cephalosporin
betalactam
patient
treat
antivir
drug
divid
patient
four
group
accord
pathogen
detect
shown
tabl
singl
viral
group
case
singl
fungalbacteri
fb
group
case
multipl
pathogen
group
case
unidentifi
pathogen
group
case
male
femal
averag
age
rang
year
group
tabl
improv
rate
singl
fb
infecti
group
singl
viral
group
unidentifi
pathogen
group
multipl
infecti
group
comparison
laboratori
paramet
white
blood
cell
wbc
count
singl
fb
group
multipl
infecti
group
higher
singl
viral
unidentifi
pathogen
group
highest
lymphocyt
count
found
unidentifi
pathogen
group
p
mean
plt
count
four
group
mean
plt
count
multipl
pathogen
group
lowest
significantli
lower
singl
viru
group
p
mean
platelet
volum
mpv
count
highest
singl
fb
group
mean
fl
higher
three
group
mean
creactiv
protein
crp
thrombocytopenia
group
higher
normal
valu
crp
mg
l
similarli
median
pct
four
group
higher
clinic
limit
detect
pct
ngml
median
valu
multipl
pathogen
group
highest
tabl
clinic
paramet
patient
without
hp
infect
also
analyz
median
ly
hpposit
patient
lower
neg
patient
p
median
paf
concentr
time
higher
hpposit
patient
neg
group
among
six
cytokin
measur
studi
signific
differ
serum
among
five
group
p
fig
howev
found
serum
level
well
paf
significantli
higher
patient
group
compar
healthi
control
p
compar
unidentifi
pathogen
group
significantli
higher
singl
viral
group
mean
concentr
pgml
p
highest
level
found
unidentifi
pathogen
group
pgml
concentr
pg
ml
highest
singl
viral
group
among
five
group
highest
paf
valu
found
singl
fb
group
ngml
similarli
concentr
paigg
healthi
peopl
lower
fever
thrombocytopenia
patient
signific
differ
compar
three
patient
group
healthi
vs
singl
viru
p
healthi
vs
singl
fb
p
healthi
vs
unidentifi
p
fig
inner
associ
also
analyz
cytokin
platelet
paramet
studi
plt
quantiti
associ
platelet
distribut
width
pdw
r
p
r
p
correl
exist
r
p
paf
r
p
crp
r
p
pct
r
p
correl
found
r
p
r
p
paf
r
p
pct
r
p
addit
correl
r
p
pct
correl
crp
r
p
correl
test
cytokin
tabl
pca
method
exploit
determin
whether
paramet
profil
reflect
diseas
statu
patient
fever
thrombocytopenia
pca
extract
four
import
princip
compon
eigenvalu
explain
total
varianc
data
set
seen
compon
il
therefor
patient
fever
thrombocytopenia
diseas
statu
evalu
would
accur
combin
platelet
paramet
inflammatori
biomark
factor
significantli
influenc
prognosi
patient
also
analyz
age
plt
quantiti
pct
among
plt
quantiti
pct
risk
factor
age
protect
factor
tabl
use
kaplanmei
surviv
curv
assess
suitabl
six
cytokin
paigg
prognost
factor
compar
prognosi
differ
type
pathogen
infect
conduct
followup
patient
hospit
admitt
discharg
surviv
inform
collect
level
cytokin
paigg
consid
stratif
variabl
surviv
time
analysi
data
show
patient
singl
fb
infect
highest
eventfre
surviv
ef
patient
singl
viral
infect
lowest
ef
patient
lower
level
paigg
tend
longer
patient
higher
level
howev
ef
patient
lower
level
paf
tend
shorter
compar
higherlevel
patient
observ
signific
differ
higher
lower
group
pvalu
km
curv
probabl
due
small
sampl
size
fig
platelet
particip
interact
pathogen
host
defens
function
host
defens
infect
receiv
much
less
attent
pathogen
microbiom
may
caus
thrombocytopenia
autoimmun
mechan
mainli
molecul
epitop
mimic
autoantigen
immunolog
recognit
previous
unexpos
autoantigen
via
bystand
activ
respons
lymphocyt
superantigenmedi
polyclon
cell
activ
exagger
cytokin
releas
studi
shown
imbal
helper
cell
th
regulatori
cell
treg
cytokin
may
mediat
pathogenesi
thrombocytopenia
close
relat
express
cytokin
ie
cytokin
ie
cytokin
treg
cytokin
consist
previou
studi
upregul
cytokin
found
patient
fever
thrombocytopenia
especi
indic
cytokin
disord
may
involv
pathogenesi
newli
diagnos
itp
notabl
thrombocytopenia
patient
significantli
higher
compar
healthi
control
viral
group
highest
among
group
moreov
result
reveal
togeth
crp
pct
strong
posit
load
mirror
pathogenesi
thrombocytopenia
paf
potent
versatil
mediat
proinflamm
secret
wbc
trigger
platelet
aggreg
activ
monocyt
encount
dengu
viru
begin
gener
paf
lead
enhanc
apoptosi
platelet
acceler
platelet
clearanc
secondari
dengu
infect
paf
concentr
patient
fever
thrombocytopenia
significantli
higher
compar
healthi
control
reveal
paf
may
involv
platelet
apoptosi
clearanc
infecti
thrombocytopenia
dosedepend
effect
paf
may
induc
releas
cytokin
affect
host
immun
respons
previou
studi
show
paf
stimul
mononuclear
cell
peripher
blood
lead
releas
viral
infect
paf
combin
lp
promot
platelet
activ
recruit
worsen
endotoxininduc
injuri
therefor
paf
cytokin
potenti
effect
vivo
modul
immun
respons
strong
associ
found
paf
paf
paf
crp
reveal
paf
interact
jointli
respons
thrombocytopenia
antibodymedi
andor
cellmedi
platelet
destruct
key
process
thrombocytopenia
antibodyinduc
immunemedi
phagocytosi
complement
activ
alloantibodi
destroy
platelet
elimin
circul
mani
patient
detect
antibodi
found
howev
studi
shown
antibodi
caus
thrombocytopenia
even
plateletassoci
antibodi
level
human
lower
detect
limit
convent
method
therefor
detect
relev
antibodi
primari
condit
diagnosi
treatment
presenc
autoantibodi
target
gpibix
effect
predictor
refractori
steroid
ivig
therapi
studi
patient
neg
paigg
test
select
patient
indic
antibodymedi
clearanc
mayb
main
reason
patient
fever
thrombocytopenia
although
inform
connect
h
pylori
infect
itp
suggest
variou
clinic
studi
studi
demonstr
h
pylori
associ
thrombocytopenia
cur
effect
antih
pylori
therapi
improv
blood
platelet
quantiti
chronic
immun
thrombocytopenia
inconsist
studi
h
pylori
caus
highest
morbid
among
bacteria
induc
thrombocytopenia
may
crossreact
h
pylori
cytotoxinrel
gene
caga
antibodi
platelet
antigen
caus
plateletacceler
clearanc
h
pyloriposit
patient
significantli
higher
level
paf
found
compar
h
pylorineg
group
involv
cytokin
pathogenesi
h
pyloriinduc
thrombocytopenia
complex
initi
believ
unfortun
mechan
h
pyloriinduc
thrombocytopenia
obscur
reveal
interact
h
pylori
thrombocytopenia
greatli
expand
choic
therapeut
option
studi
kaplanmei
surviv
curv
use
assess
prognosi
infecti
thrombocytopenia
data
show
best
therapeut
efficaci
occur
singl
fb
infecti
group
patient
group
highest
ef
worst
therapeut
efficaci
found
multipl
infecti
group
plateletviru
interact
occur
via
varieti
receptor
express
platelet
mainli
mediat
toll
like
receptor
tlr
accordingli
differ
pathogen
may
interact
special
tlr
platelet
postul
pathogen
recogn
tlr
increas
platelet
destruct
multipli
presenc
antiplatelet
antibodi
due
synergi
tlr
increas
rfcmediat
phagocytosi
tlr
activ
differ
signal
pathway
affect
cell
produc
inflammatori
cytokin
therefor
cytokin
product
may
vari
due
differ
type
microbiom
cytokin
involv
immun
function
adjust
modul
antiplatelet
antibodi
respons
b
tabl
spearman
correl
coeffici
six
cytokin
patient
fever
thrombocytopenia
pgml
pgml
pgml
level
statist
signific
p
set
indic
statist
signific
spearman
correl
level
level
respect
abbrevi
auc
area
curv
cell
may
close
relat
platelet
destruct
therefor
use
level
cytokin
stratif
variabl
ef
result
show
cytokin
play
signific
role
ef
patient
lower
level
tend
longer
ef
patient
higher
level
cytokin
previou
studi
reveal
elev
activ
phase
diseas
decreas
patient
respons
dexamethason
result
indic
cytokin
could
reflect
diseas
statu
therapeut
effect
etiolog
thrombocytopenia
viralbacteri
infect
may
also
due
nonimmunolog
mechan
virusinduc
proinflammatori
environ
often
lead
platelet
activ
virem
patient
virus
trigger
decreas
platelet
product
infect
megakaryocyt
hematopoiet
stem
cell
decreas
platelet
format
addit
virusinfect
platelet
expos
pselectin
phosphatidylserin
promot
phagocytosi
macrophag
anoth
viabl
mechan
format
mix
plateletleukocyt
aggreg
adenoviru
infect
rapidli
reduc
platelet
count
etiolog
immunolog
clinic
featur
patient
fever
thrombocytopenia
quit
complic
multipl
factor
includ
type
pathogen
cytokin
autoantibodi
particip
platelet
clearanc
find
reliabl
biomark
diagnosi
prognosi
predict
urgent
need
effect
therapi
